Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 6.90M P/E - EPS this Y 81.50% Ern Qtrly Grth -
Income -20.29M Forward P/E -0.74 EPS next Y 32.00% 50D Avg Chg -4.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -76.00%
Dividend N/A Price/Book 0.17 EPS next 5Y - 52W High Chg -97.00%
Recommedations 3.00 Quick Ratio 1.08 Shares Outstanding 510.18K 52W Low Chg 12.00%
Insider Own 4.66% ROA -29.92% Shares Float 451.21K Beta 0.61
Inst Own 12.91% ROE -302.78% Shares Shorted/Prior 2.58K/1.69K Price 1.34
Gross Margin - Profit Margin - Avg. Volume 335,922 Target Price 3.00
Oper. Margin - Earnings Date May 13 Volume 36,077 Change -4.29%
About Windtree Therapeutics, Inc.

Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead product is istaroxime which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has collaboration with Chang Gung University; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee's Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.

Windtree Therapeutics, Inc. News
05/07/24 Windtree Therapeutics Regains Compliance with Nasdaq
04/18/24 Windtree Therapeutics Announces Reverse Stock Split
04/17/24 Windtree Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Key Business Updates
04/08/24 Windtree Acquires Early-Stage, Novel Oncology Platform and Completes $1.5 Million Convertible Note Bridge Financing
02/01/24 Windtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a Research
01/31/24 Windtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic Alternatives
01/26/24 Windtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management Company
01/25/24 Windtree Eliminates $15 Million Contingent Liability to Deerfield Management Company
01/18/24 Up To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater China
01/17/24 Windtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific Region
01/02/24 Windtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a Activator
12/19/23 Istaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024
12/18/23 Windtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic Shock
11/16/23 Windtree Therapeutics Announces Issuance of New Pure SERCA2a Activator Patent
11/14/23 Sidoti Events, LLC’s Virtual November Micro-Cap Conference
11/09/23 Windtree Therapeutics Reports Third Quarter 2023 Financial Results and Provides Key Business Updates
11/08/23 Windtree to Present at the Sidoti Micro Cap Conference on November 16th
10/12/23 Windtree to Present at the ThinkEquity Conference on October 19th in New York City
10/10/23 Windtree to Participate in the Lytham Partners Fall 2023 Investor Conference on October 17th
10/03/23 Windtree to Present at the Dawson James Small Cap Growth Conference on October 12th
WINT Chatroom

User Image TonytheeInvestor Posted - 1 day ago

@Austinx @Investorrrrr they have to pay off shareholders…just have to hold on and not succumb to the FUD pressure that exists from bears/shorts…plus you don’t entered in strategic alternatives to boost shareholder value and then nothing happens some type of M&A activity on the table …company has Lees on the hook for hundreds of millions…fda news expected , drug updates, global partnerships and as I’ve previously mentioned M&A $WINT 💎

User Image Investorrrrr Posted - 1 day ago

$WINT I understand that the company has very valuable assets. But if they don't manage their money well and get deeper and deeper into debt, it won't be long before a takeover bid appears. The capitalization is not significant for the debt it has, a company interested in it will pay anything. It doesn't matter if it has a capitalization of 5,10,15,20 million dollars.

User Image MyDogKnowsStocks Posted - 2 days ago

$WINT Just popped in to see what that POS Fraser is up to. What is this asset acquisition? Does anyone know how many common shares these convertibles amount to?

User Image TobbiMag Posted - 2 days ago

$WINT Monday 5X reverse merger completed $SPY $MSFT $NVDA $NVAX

User Image TobbiMag Posted - 2 days ago

$WINT Monday 5X

User Image Austinx Posted - 2 days ago

$WINT I guess they are dropping it so Varian can get cheap shares

User Image rp6577 Posted - 2 days ago

$WINT could be one of those that you see a big run in post raise. For example, $CYCC went on a tear after they raised. Although that was partly because they cancelled an offering and did a private placement

User Image rp6577 Posted - 2 days ago

@LabPsycho I was actually thinking that earlier. It has been commented before that CNTX only has one real candidate. They could easily pick up some other cash strapped companies. For example, look at $WINT - huge $183m royalty agreement linked to a Phase 3 being completed by a partner, which is fully funded by the parter. The market cap is like $3m. I would pick that up in two seconds and put it in the back pocket

User Image TobbiMag Posted - 2 days ago

$WINT LOL

User Image jgoose93 Posted - 2 days ago

$WINT 🫨

User Image MGAP Posted - 2 days ago

$WINT will fall hard

User Image TA_Kongen Posted - 2 days ago

$LGMK $WINT $FBLG $SCPX Pending S-1s. Watch for that S-1/A. Trying to get a pump going.

User Image DrabooD Posted - 3 days ago

$WINT we’ll 499,999 days to go @Popeye989 😆 our 1 share friend is at it again

User Image NottYourDaddy Posted - 3 days ago

$WINT premium scam

User Image Dollarking Posted - 3 days ago

$WINT Varian did a merge with SDK aqusition corp in 2022. Would they really merge again? And SDK mcap is an unimpressive 10 mill.

User Image marvelousTrades Posted - 3 days ago

$WINT it has to run this week or early next week, intelligent money won't come to this company if they drop an offering without a run..

User Image SoccerPeter Posted - 3 days ago

$WINT The number of shares is reduced from 9.5 million to 0.44 million. In my opinion demand will increase, there are very few shares

User Image dmplaw1 Posted - 3 days ago

$WINT Thank you for the tax loss @WINT.

User Image Kjtt Posted - 3 days ago

$WINT sure has the feel of the old Chinese yod reversed merger which is now idex after three different name changes maybe more

User Image Inbounce Posted - 3 days ago

$WINT worst stock of the year yet?

User Image DrabooD Posted - 3 days ago

$WINT they are so shitty to us… yep another offering coming. Why didn’t they just sell the company 🤦‍♀️

User Image Austinx Posted - 3 days ago

$WINT This filing is to be completed today. Timing per Varian filing was 10am with a 9am closing the following day. I think this is the reverse merger.

User Image marvelousTrades Posted - 3 days ago

$WINT is it a offering or a shelf?

User Image Austinx Posted - 3 days ago

$WINT S-1 which is typically used in IPO. Could be a sign of reverse merger soon. Thoughts?

User Image DrabooD Posted - 4 days ago

$WINT I wonder if it’s the same person buying 1 share every morning lol

User Image Austinx Posted - 4 days ago

$WINT Does the daily chart seem bullish? Is it time?

User Image Popeye989 Posted - 4 days ago

$WINT whether or not they’ve actually been working on a drug pipeline over the last 32 years spending 800M of investor capital, i just really hope they had fun while doing it, otherwise what’s the point?

User Image harmeyerc Posted - 4 days ago

$WINT No money, they can't dilute until MC is at 75 million. That tells me we have milestone payments coming, got bought out, or Varian has cash. Either way good position to be in from a share holders perspective. I hope🙄

User Image Meta4 Posted - 4 days ago

$WINT I find it hard to believe they have spent $800 million to get to this position ... tempted to invest on that fact alone

User Image TobbiMag Posted - 4 days ago

$ASST $CETX $WINT $PLTR

Analyst Ratings
HC Wainwright & Co. Neutral Jan 3, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Fraser Craig President and CEO President and CEO Sep 27 Buy 1.0199 2,500 2,550 57,877 09/28/23
Fraser Craig President and CEO President and CEO Sep 26 Buy 0.90 2,500 2,250 55,377 09/27/23
Fraser Craig President and CEO President and CEO Apr 26 Buy 1.77 1,497 2,650 7,010 04/27/23
Fraser Craig President and CEO President and CEO Apr 25 Buy 1.89 1,315 2,485 5,513 04/26/23
Hamill John P. SVP & CFO SVP & CFO Jul 26 Buy 0.3666 3,000 1,100 72,800 07/26/22
Fraser Craig President and CEO President and CEO Jul 26 Buy 0.374 2,500 935 224,058 07/26/22
Fraser Craig President and CEO President and CEO Jun 29 Buy 0.4154 7,000 2,908 217,058 06/30/22
Fraser Craig President and CEO President and CEO Mar 16 Buy 0.9799 2,000 1,960 210,058 03/17/22
Simonson Steven SVP, Chief Medical O.. SVP, Chief Medical Officer Mar 15 Buy 0.9998 5,000 4,999 83,602 03/15/22
Fraser Craig President and CEO President and CEO Mar 15 Buy 0.9801 3,000 2,940 208,058 03/15/22
Center Laboratories, Inc. 10% Owner 10% Owner May 20 Buy 4.43 1,294,260 5,733,572 1,239,088 01/10/22
Bioengine Capital Inc. 10% Owner 10% Owner May 20 Buy 7.25 55,172 399,997 1,239,088 01/10/22
Bioengine Capital Inc. 10% Owner 10% Owner May 20 Sell 1.6 1,239,088 1,982,541 01/10/22